Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.11% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Dec 31, 2021
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-22-003969General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-259.93% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
373.68% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-292.56% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
276.73% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
77.07% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.54%
- Current
- 6.11%
- Delta
- 5.57%
- Previous
- -276.70%
- Current
- -259.93%
- Delta
- 16.77%
- Previous
- 240.20%
- Current
- 373.68%
- Delta
- 133.48%
- Previous
- -543.55%
- Current
- -292.56%
- Delta
- 250.99%
- Previous
- 471.32%
- Current
- 276.73%
- Delta
- -194.59%
- Previous
- 135.78%
- Current
- 77.07%
- Delta
- -58.71%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE CAPEX_INTENSITY_INCREASED →Transitioned To · CUE CASH_GENERATION_INCREASED →Transitioned To · CUE GROWTH_INCREASED →Transitioned To · CUE PROFITABILITY_INCREASED →Transitioned To · CUE R_AND_D_INTENSITY_DECREASED →Transitioned To · CUE SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.